{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication+to+suppress+the+immune+system", "query": { "intervention": "Medication to suppress the immune system" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Medication+to+suppress+the+immune+system&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T06:48:04.197Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03829566", "title": "Autologous Transplant To End NMO Spectrum Disorder", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Neuromyelitis Optica", "Devic's Disease", "NMO Spectrum Disorder" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "rATG", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "IVIg", "type": "BIOLOGICAL" }, { "name": "Autologous Stem Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2019-11", "completion_date": "2025-11-28", "has_results": false, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829566" }, { "nct_id": "NCT01157949", "title": "A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiac Allograft Vasculopathy" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2010-11", "completion_date": "2018-01-10", "has_results": false, "last_update_posted_date": "2019-03-14", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 1, "location_summary": "Beverly Hills, California", "locations": [ { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01157949" }, { "nct_id": "NCT06599619", "title": "Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Single agent, adjuvant anti-PD1 therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Kirkwood", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-02-20", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06599619" }, { "nct_id": "NCT03593902", "title": "Cardiac Safe Transplants for Systemic Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Systemic Sclerosis", "Scleroderma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "rATG", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "IVIg", "type": "BIOLOGICAL" }, { "name": "Autologous Stem Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 9, "start_date": "2018-05-17", "completion_date": "2019-10-09", "has_results": true, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03593902" }, { "nct_id": "NCT00135694", "title": "Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "Hepatitis C, Chronic", "Nonimmune Nonviral Causes of Liver Failure" ], "interventions": [ { "name": "calcineurin inhibitor-based immunosuppression", "type": "DRUG" }, { "name": "liver transplant", "type": "PROCEDURE" }, { "name": "corticosteroids", "type": "DRUG" }, { "name": "immunosuppression withdrawal", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2005-10", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2019-02-04", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00135694" }, { "nct_id": "NCT00787722", "title": "Hematopoietic Stem Cell Transplant in Devic's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Devic's Disease" ], "interventions": [ { "name": "Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "rATG", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 13, "start_date": "2009-10-10", "completion_date": "2018-11", "has_results": true, "last_update_posted_date": "2020-02-28", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787722" }, { "nct_id": "NCT06784947", "title": "Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Stable (MSS) Colorectal Cancer (CRC)", "Metastatic Colorectal Cancer (CRC)", "Colorectal Cancer Stage IV" ], "interventions": [ { "name": "Pre-Treatment Biopsy", "type": "PROCEDURE" }, { "name": "On-Treatment Biopsy", "type": "PROCEDURE" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2025-03-25", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06784947" }, { "nct_id": "NCT04883164", "title": "Immunity After COVID-19 Vaccination", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immunity to COVID-19" ], "interventions": [ { "name": "Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Plexision", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 300, "start_date": "2021-04-27", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2021-05-12", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04883164" }, { "nct_id": "NCT00337636", "title": "Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuronal Ceroid Lipofuscinosis" ], "interventions": [ { "name": "Surgery to implant human CNS stem cells (HuCNS-SC)", "type": "PROCEDURE" }, { "name": "Medication to suppress the immune system", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "StemCells, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "12 Years", "sex": "ALL", "summary": "18 Months to 12 Years" }, "enrollment_count": 6, "start_date": "2006-05", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2015-01-15", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00337636" }, { "nct_id": "NCT07634094", "title": "Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Bioferon", "type": "DRUG" }, { "name": "Rintatolimod", "type": "DRUG" }, { "name": "αDC1 Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Debulking Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Kalinski, Pawel, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2026-08", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-10-04T06:48:04.197Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07634094" } ] }